Tolmar Opens Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park
View Related Pages
Specialty pharmaceutical company Tolmar, Inc. (Tolmar) has officially opened its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP). The new center expands Tolmar’s capacity for developing and commercializing pharmaceutical products.
Founded in 2007, Tolmar is a pharmaceutical company recognized internationally for its advanced long-acting injectable drug delivery capabilities. Tolmar develops and manufactures specialized, long acting injectables in the areas of urology, oncology, and endocrinology. Tolmar’s leading product is used in the treatment of advanced prostate cancer and is marketed in 89 countries around the world. Tolmar’s new product development facility at Rosalind Franklin’s IRP will complement the experienced team of researchers, engineers, and operations staff at our Colorado facility. The Illinois research site also increases Tolmar’s regional presence, which includes executive offices and sales and marketing personnel in Buffalo Grove, Illinois.
“Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” said Dr. Dave Loffredo, the company’s vice president of innovation. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
Dr. Stace Porter, senior vice president of development operations for Tolmar, sees great potential for the lab located within RFU’s Research Park.
“At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores. Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”
Rosalind Franklin’s state-of-the-art, 100,000-square-foot Innovation and Research Park houses six RFU research centers, including the Center for Cancer Cell Biology, Immunology and Infection.
Dr. Joseph DiMario, RFU Executive Vice President for Research, said the university was pleased to welcome Tolmar to its roster of companies.
“We look forward to collaborations that can help accelerate new product development,” Dr. DiMario said. “The IRP provides an environment that fosters the kind of intellectual biomedical “collisions” that drive meaningful innovation.”